Making a decision on treatment options for patients diagnosed with early-stage breast cancer is an important choice and one that should be made with the best information possible. EndoPredict® can help accurately determine an individual patient’s 10-year risk of recurrence to help physicians identify which patients may consider safely forgoing chemotherapy.
Learn more
The Foresight® carrier screen can help determine whether you carry inherited health conditions that you might pass on to a child. Knowing this information before you get pregnant, or early in your pregnancy, can make a difference in your family’s well-being.
The BRACAnalysis ® test assesses a person’s risk of developing hereditary breast or ovarian cancer based on the detection of mutations in the BRCA1 and BRCA2 genes.
Myriad MyRisk™ Hereditary Cancer is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on eight primary cancer sites.
GeneSight® is a pharmacogenomics test that is clinically proven to improve medication selection when used by healthcare providers. GeneSight analyzes how an individual’s genetic variations affect his or her response to medications and provides an actionable, easy to interpret report. GeneSight is used by healthcare providers to help patients diagnosed with depression.
The first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status
BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).1,2,3
The PrequelTM prenatal screen is a non-invasive test that you can take as early as 10 weeks into your pregnancy to learn about your baby’s chance to have a chromosome condition like Down syndrome.
Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.
Please try changing the search criteria, or reset filters